EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Linagliptin loaded chitosan nanoparticles for the efficient therapy of renal fibrosis

Zhixiang Wu, Yanjuan He, Hao Deng, Yue Tan, Wangzi Gao, Jiaxin Yin, Ziqin Zeng, Jing Sun, Lijuan Zhang, Yue Li, Shentang Li

Frontiers in Pharmacology · 19.03.2026 · 17

DOI: 10.3389/fphar.2026.1773015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.03.2026. Verfasst von Zhixiang Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD), whose prevalence is rising substantially, has become a major global health challenge. In this study, we developed linagliptin-loaded chitosan nanoparticles (HCS-LGP NPs) for the treatment of renal fibrosis. The synthesized nanoparticles exhibited a uniform particle size of 178.8 ± 4.4 nm and a zeta potential of −29.9 ± 2.5 mV, along with acid-responsive drug release properties. In vitro , the HCS-LGP NPs showed efficient cellular uptake in TGF-β1-induced HK-2 cells and significantly inhibited cell proliferation by downregulating the expression of TGF-β1 and Collagen I. In vivo studies demonstrated effective renal accumulation of HCS-LGP NPs in rats with renal fibrosis. Treatment with HCS-LGP NPs significantly reduced serum creatinine, blood urea nitrogen, and the protein levels of TGF-β1 and Collagen I. Notably, the administration of HCS-LGP NPs promoted marked recovery from renal injury and markedly reduced collagen fiber deposition in rats with renal fibrosis. Histopathological analysis confirmed excellent biocompatibility, with no observable damage to the heart, liver, spleen, or lungs. These findings indicate that HCS-LGP NPs hold great potential as a targeted therapy for renal fibrosis, offering enhanced efficacy and a favorable safety profile.

Schlagwörter

Stichwörter der Autor:innen

anti-renal fibrosisbiocompatibilitychitosan nanoparticleschronickidney diseasedipeptidyl peptidase-4 inhibitordrug delivery systemlinagliptinnano-delivery carrier

Autor:innen und Institutionen

  • Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, China.
  • Department of Pediatrics, The Fourth Hospital of Changsha, Changsha Hospital of Hunan Normal University, Changsha, China.
  • Hunan Normal University School of Medicine, Changsha, China.

Zitieren

APA

Wu, Z., He, Y., Deng, H., Tan, Y., Gao, W., Yin, J., Zeng, Z., Sun, J., Zhang, L., Li, Y., & Li, S. (2026). Linagliptin loaded chitosan nanoparticles for the efficient therapy of renal fibrosis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1773015

Vancouver

Wu Z, He Y, Deng H, Tan Y, Gao W, Yin J, et al. Linagliptin loaded chitosan nanoparticles for the efficient therapy of renal fibrosis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1773015

BibTeX
@article{Wu2026,
  author = {Wu, Zhixiang and He, Yanjuan and Deng, Hao and Tan, Yue and Gao, Wangzi and Yin, Jiaxin and Zeng, Ziqin and Sun, Jing and Zhang, Lijuan and Li, Yue and Li, Shentang},
  title = {Linagliptin loaded chitosan nanoparticles for the efficient therapy of renal fibrosis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1773015}
}
Kostenlos starten →